Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.		Not used in this study.

Cell materials	Yes (indicate where	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		Not used in this study.
Primary cultures: Provide species, strain, sex of origin, genetic modification status.		Not used in this study.

Experimental animals	Yes (indicate where	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		Not used in this study.
Animal observed in or captured from the field: Provide species, sex and age where possible		Not used in this study.
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID		Not used in this study.

Plants and microbes	Yes (indicate where	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		Not used in this study.
Microbes: provide species and strain, unique accession number if available, and source		Not used in this study.

Human research participants	Yes (indicate where	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		Not applicable to this study.
Provide statement confirming informed consent obtained from study participants.		Not applicable to this study.
Report on age and sex for all study participants.		Not applicable to this study.

Design

Study protocol	Yes (indicate where	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in		Not applicable to this study.

Laboratory protocol	Yes (indicate where	n/a
Provide DOI or other citation details if detailed step-by-step		Not applicable to this study.

Experimental study design	Yes (indicate where	n/a
State whether and how the following have been done**, or** if		
Sample size determination		Not applicable to this study.
Randomisation		Not applicable to this study.
Blinding		Not applicable to this study.
Inclusion/exclusion criteria		Participants with incomplete information such as pathological type, diagnosis stage and follow-up information were removed from the study.

Sample definition and in-	Yes (indicate where	n/a
State number of times the experiment was replicated in		Not applicable to this study.
Define whether data describe technical or biological replicates		Not applicable to this study.

Ethics	Yes (indicate where	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s),		Not applicable to this study.
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide		Not applicable to this study.
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		We did biopsy before any anti-cancer treatment. Experimental plans and protocols for this study (No. K18-203Y) were approved by the ethics/licensing committee of the Shanghai Pulmonary Hospital for review and confirmation. Written informed consent was obtained from all patients participating in the study. All experiments, methods, procedures, and personnel training were carried out in accordance with relevant guidelines and regulations of the participating hospitals and laboratories.

Dual Use Research of Concern	Yes (indicate where	n/a
If study is subject to dual use research of concern, state the authority granting approval and		Not applicable to this study.

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion		Not applicable to this study.

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	Fisher's exact test or a non-parametric test was employed to correlate clinical and biological variables when necessary. The PFS and OS were calculated using the Kaplan-Meier method, and differences in variables were compared using log-rank tests.	

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction	The raw sequencing data is available in NCBI BioProject (612728).	
If data are publicly available, provide accession number in repository or DOI or URL.		Not applicable to this study.
If publicly available data are reused, provide accession number in repository or DOI or URL, where		Not applicable to this study.

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:	The codes used in this study are stored at https://github.com/wanglei-md/BioinformaticsScripts.	Not applicable to this study.
State whether the code or software is available.		Not applicable to this study.
If code is publicly available, provide accession number in repository, or DOI or URL.		Not applicable to this study.

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		Not applicable to this study.
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article Information: http://dx.doi.org/10.21037/tlcr-20-1096